New pill targets common cancer mutation in early trial
NCT ID NCT06585488
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The main goals were to check safety and find the right dose, but the study was stopped early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-53038 (a Pan-KRAS inhibitor pill), sometimes combined with tislelizumab or cetuximab infusions
What this could lead to
If it works, this could point toward a new treatment option for several hard-to-treat cancers with KRAS mutations.
What could go wrong
This is a very early (phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, 05505, South Korea
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, VIC 3000, Australia
-
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
Baltimore, Maryland, 21287, United States
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
University of Kansas Medical Center Research Institute
Kansas City, Kansas, 66160-8500, United States
-
Usc Norris Comprehensive Cancer Center (Nccc)
Los Angeles, California, 90089-1019, United States